Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update • Initial Phase 2 data of BDTX-1535 in 2L/3L patients with EGFRm NSCLC on track for later in Q3 2024 • On track to announce initial Phase 2 data of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC in Q1 2025, and initial Phase 1 data of BDTX-4933 in KRASm NSCLC in Q4 2024 • Upcoming poster presentation at 2024 ESMO Congress in September, titled "Real World Evidence of Treatment Practices and Therape ...

Core Insights - Black Diamond Therapeutics presented promising results from the Phase 1 dose escalation trial of BDTX-1535 in recurrent glioblastoma (GBM) patients, showing a favorable safety profile and encouraging anti-tumor activity [1][2][3] Group 1: Clinical Trial Results - The Phase 1 trial demonstrated a duration of treatment exceeding the typical two to four months expected in recurrent GBM, with good safety and tolerability at therapeutic doses [2] - Among 19 efficacy evaluable patients, several experienced stable disease with promising durability [3] - Initial data from a Phase 0/1 "trigger" trial indicated that BDTX-1535 achieved clinically meaningful drug levels in brain tumor tissue, exceeding the pre-specified PK threshold of 4.1 nM [4][10] Group 2: Safety and Tolerability - BDTX-1535 was generally well tolerated, with treatment-related adverse events primarily mild to moderate, including rash, diarrhea, and fatigue [5][10] - No grade 3 or higher treatment-related adverse events were reported at doses of BDTX-1535 ≤100 mg/day, with only one grade 3 rash observed at 200 mg [5] Group 3: Pharmacokinetics and Pharmacodynamics - Eight out of nine patients (88.9%) exceeded the PK threshold of 4.1 nM unbound drug concentration, with average concentrations of 11.9 nM for the 200 mg dose and 18.8 nM for the 400 mg dose [10] - BDTX-1535 was associated with suppression of EGFR-mediated signaling, as determined by several pharmacodynamic markers [10] Group 4: Future Directions - The company is considering further trials of BDTX-1535 in newly diagnosed patients with confirmed EGFR mutations based on the clinical activity observed [6]

Investors are always looking for stocks that are poised to beat at earnings season and Black Diamond Therapeutics, Inc. (BDTX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Black Diamond Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date informati ...

• the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval; • the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims; Table of Contents If we raise additional funds through collaborations, strategic partnerships and alliances or mark ...

• Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025 • Cash, cash equivalents, and investments of $115.2 million as of March 31, 2024, expected to be sufficient to fund operations into Q3 of 2025 • Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024 • Poster presentations upcoming June 1 at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-escalation data and initial "window of oppor ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the st ...

Black Diamond (BDTX) closed the last trading session at $5.06, gaining 3.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $12.80 indicates a 153% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $2.59. While the lowest estimate of $10 indicates a 97.6% increase from the current price level, the most optimistic analyst expects ...

Black Diamond (BDTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The pow ...

CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These ...

Shares of Black Diamond (BDTX) have gained 24.6% over the past four weeks to close the last trading session at $5.06, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.60 indicates a potential upside of 129.3%.The average comprises five short-term price targets ranging from a low of $10 to a high of $15, with a standard deviation of $2.07. While the lowest estimate indicates a ...